Glaukos Reports Positive Phase 4 Results For IDose TR With Cataract Surgery
(RTTNews) - Friday, Glaukos Corporation (GKOS) announced positive topline results from a Phase 4 study evaluating iDose TR in combination with cataract surgery in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
The study met its primary endpoint, with iDose TR plus cataract surgery demonstrating statistically significant superiority in reducing mean diurnal intraocular pressure (IOP) compared with cataract surgery alone.
At three months, patients receiving iDose TR along with cataract surgery achieved a mean IOP reduction of 11.1 mmHg from baseline, versus 7.4 mmHg with cataract surgery alone.
GKOS closed Thursday's trading at $161.29, down 6.32%. In pre-market trading the stock is at $163.50, up 1.37%.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.